SC 13D/A

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

SCHEDULE 13D

[Rule 13d-101]

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d -1(a)
AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d -2(a)

(Amendment No. 4)*

CHINA BIOLOGIC PRODUCTS, INC.
(Name of Issuer)

COMMON STOCK, PAR VALUE $0.0001 PER SHARE
(Title of Class of Securities)

16938C106
(CUSIP Number)

No. 14 East Hushan Road
Tai'an City, Shandong 271000
People's Republic of China
(86) 538-620-2306
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

March 14, 2012
(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d -1(e), 240.13d -1(f) or 240.13d -1(g), check the following box [ ].

CUSIP No. 16938C106 13D Page 2 of 6 pages

1.	NAMES OF REPORTING PERSONS Lin Ling Li
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [    ] (b) [    ]
3.	SEC USE ONLY
4.	SOURCE OF FUNDS PF
5.	CHECK  BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)   [   ]
6.	CITIZENSHIP OR PLACE OF ORGANIZATION   People's Republic of China
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7.	SOLE VOTING POWER 4,592,624(1)
		8.	SHARED VOTING POWER 0
		9.	SOLE DISPOSITIVE POWER 4,592,624(1)
		10.	SHARED DISPOSITIVE POWER 0
11.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 4,592,624(1)
12.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES   [   ]
13.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 17.9% (2)
14.	TYPE OF REPORTING PERSON   IN

(1)	Includes 50,000 shares of common stock issuable upon the exercise of a ten-year nonstatutory stock option granted to the Reporting Person by the Issuer under the Issuer's 2008 Equity Incentive Plan, exercisable within sixty (60) days of this report at $4.00 per share.
(2)	All percentage calculations set forth herein are based on 25,601,125 shares of Common Stock outstanding as of March 9, 2012 as reported on the Issuer's most recent annual report on Form 10-K for the year ended December 31, 2011, filed with the Securities and Exchange Commission on March 12, 2012.

CUSIP No. 16938C106 13D Page 3 of 6 pages

ITEM 1. Security and Issuer.

This Amendment No. 4 to Schedule 13D relates to the common stock, par value $0.0001 per share (the "Common Stock"), of China Biologic Products, Inc., a Delaware corporation (the "Issuer"), which has its principal executive offices located at No. 14 East Hushan Road, Tai'an City, Shandong, 271000, People's Republic of China. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.

ITEM 2. Identity and Background.

(a) This Amendment No. 4 to Schedule 13D is being filed by Lin Ling Li (the "Reporting Person").

(b) The business address of the Reporting Person is 14 East Hushan Road, Tai'an City, Shandong, 271000, People's Republic of China.

(c) Ms. Li is a principal shareholder of the Issuer.

(d) During the last five years, the Reporting Person has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

(e) During the last five years, the Reporting Person has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

(f) The Reporting Person is a citizen of the People's Republic of China.

ITEM 3. Source and Amount of Funds or Other Consideration.

The Reporting Person received the securities covered by this statement pursuant to that certain share exchange agreement (the "Share Exchange Agreement") by and among the Issuer, Logic Express Limited ("Logic Express") and its stockholders. Upon the closing of the Share Exchange Agreement on July 18, 2006, Logic Express became a wholly-owned subsidiary of the Issuer and the former stockholders of Logic Express, including the Reporting Person, owned approximately 96.1% of the Issuer immediately prior to the private placement described below. The Reporting Person received 7,902,624 shares of the Issuer's Common Stock.

On July 18, 2006, the Issuer also completed a private placement transaction with a group of accredited investors. Pursuant to that certain securities purchase agreement, as amended (the "Securities Purchase Agreement" and together with the Share Exchange Agreement, the "Agreements"), the Issuer sold 2,200,000 shares of its Common Stock and five-year warrants to purchase 1,070,000 shares of the Issuer's Common Stock at an exercise price of $2.8425 per share, and at a purchase price of $1.895 per unit. In addition, the Reporting Person sold an aggregate of 1,040,000 shares of the Issuer's Common Stock at a price of $1.895 per share to the same investors. Following the consummation of the Securities Purchase Agreement, the Reporting Person owned 6,862,624 shares of the Issuer's Common Stock.

On May 30, 2010, the Reporting Person and another stockholder of the Issuer, Siu Ling Chan, entered into a stock purchase agreement (the "Stock Purchase Agreement") with Warburg Pincus Private Equity X, L.P. and Warburg Pincus X Partners, L.P. (collectively, "Warburg Pincus"), whereby subject to the satisfaction of certain closing conditions, the Reporting Person agrees to sell an aggregate of 1,500,000 shares of the Issuer's Common Stock at a price of $13.00 per share to Warburg Pincus.

On August 31, 2010, the Reporting Person entered into a separate stock purchase agreement (the "Second Stock Purchase Agreement") with Warburg Pincus, whereby the Reporting Person sold an aggregate of 770,000 shares of the Issuer's Common Stock at a price of $13.00 per share to Warburg Pincus. The closing of the sale occurred on the same day. Immediately after the closing, the Reporting Person beneficially owned 6,142,624 shares of the Issuer's Common Stock.

On December 10, 2010, the transactions contemplated in the Stock Purchase Agreement dated May 30, 2010 closed. Immediately upon such closing, the Reporting Person beneficially owns 4,592,624 shares of the Issuer's Common Stock. In addition, after the closing, upon the request of Warburg Pincus, as long as the Reporting Person continues to beneficially own five percent (5%) or more of the total outstanding voting stock of the Issuer, the Reporting Person is obligated to use her best efforts to cause an individual nominated by Warburg Pincus to promptly become elected or appointed as a director of the Issuer, so far as such individual is not prohibited by any applicable law or stock exchange rules to be a public company director.

The Reporting Person has used her best efforts to obtain, and the Company has executed and delivered, a registration rights agreement with respect to the shares sold by the Reporting Person to Warburg Pincus, a copy of which is attached hereto as Exhibit 7, which is required pursuant to the Stock Purchase Agreement.

The 4,592,624 shares of Common Stock beneficially owned by the Reporting Person and reported herein also include options to purchase 50,000 shares of Common Stock that are fully vested and currently exercisable or will become exercisable within sixty (60) days of the date hereof at an exercise price of $4.00 per share. The options held by the Reporting Person were issued to the Reporting Person under the Issuer's 2008 Equity Incentive Plan (the "Plan") as compensation for her services as a Director of the Issuer.

CUSIP No. 16938C106 13D Page 4 of 6 pages

ITEM 4. Purpose of Transaction.

The Reporting Person acquired the Common Stock pursuant to the Agreements and the Plan as described in Item 3 above. In connection with the Share Exchange Agreement, there were changes to the Issuer's board of directors which were more fully described in the registration statement on Form SB-2 filed by the Issuer on September 5, 2007. In addition, as described in Item 3 above, the Reporting Person entered into the Stock Purchase Agreement with Warburg Pincus on May 30, 2010 and, upon the closing of the transactions contemplated in the Stock Purchase Agreement on December 10, 2010, the Reporting Person is obligated to use her best efforts to cause an individual nominated by Warburg Pincus to be elected or appointed as a director of the Issuer, so far as such individual is not prohibited by any applicable law or stock exchange rules to be a public company director. The Reporting Person has used her best efforts to obtain, and the Company has executed and delivered, a registration rights agreement with respect to the shares sold by the Reporting Person to Warburg Pincus, a copy of which is attached hereto as Exhibit 7, which is required pursuant to the Stock Purchase Agreement.

On March 16, 2012, seeking to obtain written consent (the “Written Consent”) of stockholders holding a majority of the voting power of all outstanding capital stock of the Company to approve certain actions (the “Proposed Actions”) in accordance with Section 228 of the Delaware General Corporation Law (“DGCL”) and Section 2.07 of Article II of the Amended and Restated Bylaws of the Company (the “Bylaws”), the Reporting Person delivered a written request (the “Request”) for stockholder written consent to certain stockholders of the Company. The Proposed Actions include the (i) removal of Dr. Tong Jun Lin (“Dr. Lin”) from the Board in accordance with Section 141(k) of DGCL and Section 3.03 of the Bylaws, and (ii) election of Mr. Joseph Chow (“Mr. Chow”) to the Board to fill the vacancy resulting from the removal of Dr. Tong Jun Lin in accordance with Section 3.03 of the Bylaws. A copy of the Request (including the form of Written Consent attached thereto) is attached to this Schedule 13D/A as Exhibit 8.

Pursuant to Rule 14a-2(b)(2) under the U.S. Securities Exchange Act of 1934, as amended (the “Exchange Act”), the Request did not constitute a general solicitation of stockholder consent under the proxy rules under the Exchange Act as the Request was delivered to no more than ten stockholders of the Company.

As of the date of the filing of this Schedule 13D/A, the Reporting Person has received (i) Written Consents signed by individual record holders of 5,392,624 shares of Common Stock and (ii) notices from the beneficial owners of 2,152,841 shares of Common Stock held by institutional record owners that they have instructed the applicable record holder of their respective shares of Common Stock to execute the Written Consent and return to the Reporting Person. If the Reporting Person is able to secure Written Consents signed by stockholders owning at least a majority of the outstanding capital stock of the Company, i.e., at least 12,800,563 shares of Common Stock, the Proposed Actions will take effect pursuant to Section 228 of the DGCL upon the delivery of a copy of such signed Written Consents to the Company.

As of March 19, 2012, the Reporting Person has delivered Written Consents signed by record holders holding 5,392,624 shares of Common Stock to the Company's registered office in Delaware and principal executive office in Beijing, China.

Except as set forth in this Schedule 13D/A and the registration statement on Form SB-2 referred to above, the Reporting Person has not made any proposals, and has not entered into any agreements, which would be related to or would result in any of the events or matters described in part (a) through (j) of Item 4 of Schedule 13D.

ITEM 5. Interest in Securities of the Issuer.

(a) As of the date of this Schedule 13D/A, the Reporting Person beneficially owns 4,592,624 shares of Common Stock (which includes 50,000 shares of Common Stock issuable upon the exercise of options held by the Reporting Person), which represents approximately 17.9% of the issued and outstanding shares of Common Stock of the Issuer. The Reporting Person does not own any other securities of the Issuer.

(b) The Reporting Person has the sole power to vote, or direct the vote of 4,542,624 shares of Common Stock and the sole power to dispose of, or direct the disposition of, 4,592,624 shares of Common Stock (which includes 50,000 shares of Common Stock issuable upon the exercise of options held by the Reporting Person), which represents approximately 17.9% of the outstanding shares of Common Stock of the Issuer.

(c) The Reporting Person has not effected any transactions in the Issuer's securities within the past sixty (60) days.

(d) Other than the Reporting Person, no other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the Reporting Person's securities.

ITEM 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

Except as disclosed in this Schedule 13D/A and in the registration statement on Form SB-2 filed by the Issuer on September 5, 2007, there are no contracts, arrangements, understandings or relationships (legal or otherwise) among the Reporting Person and any other person with respect to any securities of the Issuer, including, but not limited to transfer or voting of any of the securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies.

As disclosed in Item 3 above, on August 31, 2010, the Reporting Person sold 770,000 shares to Warburg Pincus under the Stock Purchase Agreement dated the same day, and on December 10, 2010, the Reporting Person sold an aggregate of 1,500,000 shares of the Issuer's Common Stock at a price of $13.00 per share to Warburg Pincus pursuant to the Stock Purchase Agreement dated May 30, 2010. Immediately following the consummation of the transactions contemplated in the Stock Purchase Agreement, the Reporting Person beneficially owns 4,592,624 shares of the Issuer's Common Stock. The Reporting Person has used her best efforts to obtain, and the Company has executed and delivered, a registration rights agreement with respect to the shares sold by the Reporting Person to Warburg Pincus, a copy of which is attached hereto as Exhibit 7, which is required pursuant to the Stock Purchase Agreement.

ITEM 7. Materials to be Filed as Exhibits.

Exhibit 1	Share Exchange Agreement among the Issuer, Logic Express and the selling stockholders signatory thereto, dated as of July 18, 2006, incorporated by reference to Exhibit 2.1 to the Issuer's registration statement on Form SB-2 filed on September 5, 2007
Exhibit 2	Securities Purchase Agreement among the Issuer, Logic Express, Shandong Missile Biologic Products Co., Ltd., and the selling stockholders and investors signatory thereto, dated as of July 18, 2006 incorporated by reference to Exhibit 4.1 to the Issuer's registration statement on Form SB-2 filed on September 5, 2007
Exhibit 3	Issuer's 2008 Equity Incentive Plan, incorporated by reference to Exhibit 10.1 of the current report on Form 8-K, filed by the Issuer on May 13, 2008
Exhibit 4	Form of Stock Option Award Agreement of Issuer, incorporated by reference to Exhibit 10.5 of the current report on Form 8-K, filed by the Issuer on May 13, 2008
Exhibit 5	Stock Purchase Agreement among Warburg Pincus Private Equity X, L.P., Warburg Pincus X Partners, L.P. and the selling stockholders signatory thereto, dated as of May 30, 2010, incorporated by reference to Exhibit 5 of the Schedule 13D/A, filed by the Reporting Person on June 25, 2010
Exhibit 6	Stock Purchase Agreement among Warburg Pincus Private Equity X, L.P., Warburg Pincus X Partners, L.P. and the selling stockholders signatory thereto, dated as of August 31, 2010, incorporated by reference to Exhibit 6 of the Schedule 13D/A, filed by the Reporting Person on September 3, 2010
Exhibit 7	Registration Rights Agreement among Warburg Pincus Private Equity X., L.P., Warburg Pincus X. Partners, L.P. and China Biologic Products, Inc., dated as of December 10, 2010, incorporated by reference to Exhibit 4.1 of the current report on Form 8-K, filed by the Issuer on September 14, 2010
Exhibit 8	Reporting Person Request (including the form of Written Consent attached thereto)

CUSIP No. 16938C106 13D Page 5 of 6 pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I hereby certify that the information set forth in this statement is true, complete and correct.

EXECUTED as a sealed instrument this   19th   day of March, 2012.

LIN LING LI

By: /s/ Lin Ling Li                             
Name: Lin Ling Li

CUSIP No. 16938C106 13D Page 6 of 6 pages

Exhibit 1	Share Exchange Agreement among the Issuer, Logic Express and the selling stockholders signatory thereto, dated as of July 18, 2006, incorporated by reference to Exhibit 2.1 to the Issuer's registration statement on Form SB-2 filed on September 5, 2007
Exhibit 2	Securities Purchase Agreement among the Issuer, Logic Express, Shandong Missile Biologic Products Co., Ltd., and the selling stockholders and investors signatory thereto, dated as of July 18, 2006 incorporated by reference to Exhibit 4.1 to the Issuer's registration statement on Form SB-2 filed on September 5, 2007
Exhibit 3	Issuer's 2008 Equity Incentive Plan, incorporated by reference to Exhibit 10.1 of the current report on Form 8-K, filed by the Issuer on May 13, 2008
Exhibit 4	Form of Stock Option Award Agreement of Issuer, incorporated by reference to Exhibit 10.5 of the current report on Form 8-K, filed by the Issuer on May 13, 2008
Exhibit 5	Stock Purchase Agreement among Warburg Pincus Private Equity X, L.P., Warburg Pincus X Partners, L.P. and the selling stockholders signatory thereto, dated as of May 30, 2010, incorporated by reference to Exhibit 5 of the Schedule 13D/A, filed by the Reporting Person on June 25, 2010
Exhibit 6	Stock Purchase Agreement among Warburg Pincus Private Equity X, L.P., Warburg Pincus X Partners, L.P. and the selling stockholders signatory thereto, dated as of August 31, 2010, incorporated by reference to Exhibit 6 of the Schedule 13D/A, filed by the Reporting Person on September 3, 2010
Exhibit 7	Registration Rights Agreement among Warburg Pincus Private Equity X., L.P., Warburg Pincus X. Partners, L.P. and China Biologic Products, Inc., dated as of December 10, 2010, incorporated by reference to Exhibit 4.1 of the current report on Form 8-K, filed by the Issuer on September 14, 2010
Exhibit 8	Reporting Person Request (including the form of Written Consent attached thereto)

EX-8

Exhibit 8

REQUEST FOR STOCKHOLDER CONSENT TO ACTION

Ms. Lin Ling Li
10B Nanfu Building, Zhongfu Lakeside Garden
66 Hubin Road, Fuzhou, China
Phone: +86 59 1983772219
Fax: +86 59 188500795
E-mail: lll@ctbb.com.cn

DATED: MARCH 15, 2012

To :                                                            

On behalf of the undersigned stockholder, we are sending this written notice to you to seek your consent to the accompanying action by written consent of stockholders of China Biologic Products Inc., a Delaware corporation (the “Company”), to (i) remove Dr. Tong Jun Lin, without cause, from his current position as director of the Company and (ii) elect Joseph Chow to fill the vacancy on the board of directors resulting from the removal of Dr. Tong Jun Lin. As explained in more details in the attached informational document, we are seeking to contact no more than ten (10) stockholders of the Company owing at least a majority of the outstanding common stock of the Company to seek their written consents to approve the proposed director change.

If you agree with the proposed action by written consent set forth herein, please sign the accompanying written consent which we will notify the Company in accordance with the Delaware General Corporation Law (the “DGCL”). Please return the signed written consent (including all pages) to the Beijing office of DeHeng Law Offices:

by fax to:	+86-10-6523-2180
	Attention: Mr. Xu Zhang
and email to:	zhangxu@dehenglaw.com

and followed by mailing of the original signed written consent to:

DeHeng Law Offices
Tower B, 12^th Floor
Focus Place
19 Finance Street
Beijing, China 100032
Attention: Mr. Xu Zhang

IN REGARD TO THIS REQUEST WE ARE CONTACTING NO MORE THAN TEN (10) STOCKHOLDERS OF THE COMPANY IN RELIANCE UPON RULE 14a-2(b)(2) UNDER THE U.S. SECURITIES EXCHANGE ACT OF 1934, AS AMENDED (THE “EXCHANGE ACT”). THIS NOTICE DOES NOT CONSTITUTE A GENERAL SOLICITATION OF STOCKHOLDER CONSENTS UNDER THE PROXY RULES UNDER THE EXCHANGE ACT.

THIS NOTICE IS PROVIDED TO SEEK YOUR WRITTEN CONSENT PURSUANT TO THE DGCL AND DOES NOT CONSTITUTE A PROXY STATEMENT OR INFORMATION STATEMENT UNDER THE EXCHANGE ACT.

Sincerely,

Ms. Lin Ling Li

Ms. Lin Ling Li
10B Nanfu Building, Zhongfu Lakeside Garden
66 Hubin Road, Fuzhou, China
Phone: +86 59 1983772219
Fax: +86 59 188500795
E-mail: lll@ctbb.com.cn

March 15, 2012

Summary of the Corporate Actions

I am the owner, beneficially and of record, of 4,592,624 shares of common stock of the Company as of the date hereof. I am requesting that you execute the attached action by written consent of stockholders to (i) remove Dr. Tong Jun Lin, without cause, from his position as director of the Company and (ii) elect Joseph Chow to fill the vacancy on the board of directors resulting from the removal of Dr. Tong Jun Lin. This request is being made without the involvement of the Company or its board of directors. If I am able to secure signatures to the action by written consents from stockholders owning at least a majority of the outstanding common stock of the Company, the action by written consents will take effect pursuant to Section 228 of the DGCL upon our delivery of a copy of such signed written consents to the Company. I will also request the Company to deliver, pursuant to Section 228(e) of the DGCL, a notice of the action by written consents to the Company’s other stockholders who did not sign such action by written consent.

I believe it is in the best interest of the Company that Dr. Tong Jun Lin be removed from the board and Mr. Joseph Chow be elected to fill the resulting vacancy. While Dr. Lin has a very distinguished academic career in the area of immunology, he has a limited business background or experience. Mr. Chow has extensive business experience in finance and the management of public and private companies. As noted in his biography below, he is currently a director of two Nasadaq companies as well as a company that trades on the Hong Kong Stock Exchange. In addition, Mr. Chow qualifies as an independent director under NASDAQ's listing Rules 5605(a)(2) and (c)(2) and SEC Rule 10A-3(b)(1). I believe it would be in the best interest of the Company and its stockholders to have an independent director with an extensive business background and the director appointment of Mr. Chow will improve the corporate governance of the Company.

Joseph Chow has over 18 years of experience in corporate finance, financial advisory and management and has held senior executive and managerial positions in various public and private companies. He has served as an independent director of China Lodging Group, Limited (Nasdaq: HTHT) since August 2010 and a director of Synutra International, Inc. (Nasdaq: SYUT) since May 4, 2010. Mr. Chow was a managing director of Goldman Sachs (Asia) LLP from 2008 to 2009. Prior to that, he served as an independent financial consultant from 2006 to 2008, as chief financial officer of Harbor Networks Limited from 2005 to 2006, and as chief financial officer of China Netcom (Holdings) Company Limited from 2001 to 2004. Prior to that Mr. Chow also served as the director of strategic planning of Bombardier Capital, Inc., as vice president of international operations of Citigroup and as the corporate auditor of GE Capital. Mr. Chow currently is an independent non-executive director for Kasen International Holdings Limited and for Intime Department Store (Group) Co., Ltd. Mr. Chow obtained a Bachelor of Arts degree in political science from Nanjing Institute of International Relations and an MBA from the University of Maryland at College Park.

A copy of Mr. Chow’s resume is attached to the action by written consent accompanying this notice.

This request is being sent to you on or about March 15, 2012.

Voting and Vote Required

I am seeking your consent to the action by written consent accompanying this notice. Under the DGCL and the Company’s Bylaws, the removal of a director and the filling of vacancies may be effected by the written consent of stockholders holding a majority of the voting power of all of our capital stock.

As of the date of this Notice, the Company had 25,601,125 shares of common stock outstanding and entitled to vote. Each share of common stock is entitled to one vote. I am seeking consent from, and only contacting, no more than ten (10) stockholders owning at least 12,826,163 shares of common stock, representing approximately 50.1% of the Company’s voting power. Accordingly, the written consent executed by such stockholders would be sufficient to approve the actions contemplated herein and such action by written consents will take effect pursuant to Section 228 of the DGCL upon our delivery of a copy of such signed written consents to the Company.

2

Notice Pursuant to the Company’s Bylaws and Delaware General Corporation Law

Pursuant to Section 228(e) of the DGCL, the Company is required to provide prompt notice of the taking of a corporate action by written consent to the Company’s stockholders who have not consented in writing to such action. Upon the execution of the action by written consent accompanying this notice, I will send a copy of such written consent to the Company, and will request the Company to prepare and send out the notice required by Section 228(e) of the DGCL.

This notice is not intended to serve as the notice required under Section 228(e) of the DGCL.

Appraisal Rights

Stockholders of the Company are not entitled to appraisal rights under the DGCL in connection with the director changes.

AVAILABLE INFORMATION

The Company’s reports, proxy statements and other information filed with the SEC can be inspected and copied at the public reference facilities of the SEC at Room 1580, 100 F Street, NE, Washington, D.C. 20549. Copies of this material can also be obtained at prescribed rates by writing to the Public Reference Section of the Commission at Room 1580, 100 F Street, NE, Washington, D.C. 20549. In addition, these reports, proxy statements and other information are available through the SEC’s website (http://www.sec.gov).

THIS NOTICE IS PROVIDED TO SEEK YOUR WRITTEN CONSENT PURSUANT TO THE DGCL AND DOES NOT CONSTITUTE A PROXY STATEMENT OR INFORMATION STATEMENT UNDER THE EXCHANGE ACT.

ACTION BY WRITTEN CONSENT
IN LIEU OF A SPECIAL MEETING
OF THE STOCKHOLDERS OF
CHINA BIOLOGIC PRODUCTS, INC.
a Delaware corporation

In accordance with Section 228 of the Delaware General Corporation Law (“DGCL”) and Section 2.07 of Article II of the Amended and Restated Bylaws of China Biologic Products, Inc. (the “Company”), the undersigned stockholders of the Company, representing a majority of the outstanding shares of the Company's common stock as of the date of the delivery of this Written Consent to the Company, do hereby, pursuant to this Written Consent, vote all shares of the Company's outstanding voting stock held of record by the undersigned FOR the adoption and approval of the following resolutions, without a formal meeting and without prior notice, effective upon the delivery of this Written Consent to the Company:

1. Removal of Director Without Cause.

WHEREAS, under Section 141(k) of the DGCL and Section 3.03 of Article III of the Amended and Restated Bylaws of the Company (the “Bylaws”), any member of the Board of Directors of the Company (the “Board”) may be removed, with or without cause, by a vote of the stockholders of the Company holding a majority of the outstanding shares of the Company;

WHEREAS, the undersigned stockholders deem it to be in the best interest of the Company to remove Dr. Tong Jun Lin from the Board and elect Mr. Joseph Chow, whose resume (in English and Chinese) is attached to this Written Consent as Exhibit A, to fill the vacancy created by the removal of Dr. Tong Jun Lin; and

WHEREAS, after careful consideration, the stockholders have determined that it is in the best interest of the Company and the stockholders of the Company to remove Dr. Tong Jun Lin from the Board and elect Mr. Joseph Chow to fill the vacancy created by such removal.

NOW, THEREFORE, BE IT RESOLVED, that effective upon the delivery of this Written Consent to the Company, Dr. Tong Jun Lin is hereby removed from the Board and any committee of the Board on which he may be then serving, without cause, subject to the Company’s policy in regard to director compensation (including, but not limited, the vesting and/or forfeiture of any equity compensation granted to Dr. Tong Jun Lin) upon a director’s removal from the Board.

1

2. Election of Director to Fill Vacancy

RESOLVED, that in accordance with Section 3.02 of Article III and Section 2.07 of Article II of the Bylaws, the undersigned stockholders hereby elect Mr. Joseph Chow to the Board to fill the vacancy on the Board resulting from the removal of Dr. Tong Jun Lin.

3. Cancellation of Adverse Board or Officer Actions

RESOLVED, that any and all actions taken by the Board or any officer of the Company (including without limitation amendments to the Bylaws and any other resolution of the Board) that may cause any adverse effect on the carrying out of the purposes of the foregoing resolutions or the taking effect of the aforementioned replacement of director, including without limitation delays or creation of procedural hurdles, be, and hereby are, revoked, cancelled and rescinded in their entirety automatically without any additional action by the stockholders of the Company, the Board or the officers of the Company.

4. General.

RESOLVED, that the officers of the Company be, and they hereby are, directed and instructed to promptly execute any applications, certificates, agreements or any other instruments or documents or amendments or supplements to such documents, or do or cause to be done any and all other acts and things that are necessary or required to carry out the purposes of the foregoing resolutions.

This Written Consent may be executed in two or more counterparts, each of which shall be deemed an original but all of which together shall constitute the same written consent.

[Remainder of page intentionally left blank]

2

IN WITNESS WHEREOF, the undersigned stockholders of the Company, hereby voting the full number of shares of the Company's outstanding voting stock held of record by such stockholders, have executed this Written Consent and direct that this Written Consent be filed with the minutes of the proceedings of the Company's stockholders and that prompt written notice of this action be given to any stockholders of the Company who have not executed this Written Consent.

Signature:

Name of Record Stockholder:

Authorized Signatory:

Date signed:

No. of Company shares owned as of signing date:                           

3

EXHIBIT A
Joseph Chow

Experience:	Moelis & Company	Beijing, China
	Managing Director - CEO of China	2011.06
	Synutra International (NASDAQ:SYUT)	Beijing, China
	Interim CFO and Director	2009.10-2011.5
	Goldman Sachs Asia L.L.C	Beijing, China
	Managing Director - Private Finance Group	2008,04 –2009.07
	CJC Partners	2006.3-2008.3
	Managing Partner
	Harbour Networks Limited.	Beijing, China
	Chief Financial Officer	2005,03 ---2006.03
	China Netcom Holding Corp.	Beijing, China
	VP and Chief Financial Officer	2001,10---2004,10
	Bombardier Capital Inc.	Colchester, VT
	Director and Head – Strategic Planning	2001, 1—2001.7
	CitiGroup	Irving, TX
	Vice President – Credit and Risk Management	1997, 1 – 2001. 1
	General Electric	Fairfield, CT
	Corporate Auditor	1996.1-1996.12
	GE Capital	Danbury, CT
	Associate	1993.6 - 1996. 1
	NORINCO - China	Harare, Zimbabwe
	Representative - Southern Africa	1987.6 - 1989.10
Education:	University of Maryland at College Park	College Park, MD
	MBA - Corporate and International Finance	1993.5
	Nanjing Institute of International Relations	Nanjing, China
	BA - Political Science	1984.7
Directorship:	China Lodging Group ( NASDAQ: HTHT)
	China Intime Department Stores: (HKSE:1833)
	Synutra International (NASDAQ: SYUT)

4